An efficient framework for robust sample size determination
Open Access
- 20 November 2026
- journal article
- Published by SAGE Publications in Statistical Methods in Medical Research
Abstract
In many settings, robust data analysis involves computational methods for uncertainty quantification and statistical inference. To design frequentist studies that leverage robust analysis methods, suitable sample sizes to achieve desired power are often found by estimating sampling distributions of p -values via intensive simulation. Moreover, most sample size recommendations rely heavily on assumptions about a single data-generating process. Consequently, robustness in data analysis does not by itself imply robustness in study design, as examining sample size sensitivity to data-generating assumptions typically requires further simulations. We propose an economical alternative for determining sample sizes that are robust to multiple data-generating mechanisms. Applying our theoretical results that model p -values as a function of the sample size, we assess power across the sample size space using simulations conducted at only two sample sizes for each data-generating mechanism. We demonstrate the broad applicability of our methodology to study design based on M-estimators in both experimental and observational settings through a varied set of clinical examples.Funding Information
- The University of Queensland's Health Research Accelerator initiative
This publication has 39 references indexed in Scilit:
- Testing for underpowered literaturesJournal of Econometrics, 2026
- Design of Bayesian Clinical Trials With Clustered DataStatistics in Medicine, 2026
- Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trialsGastric Cancer, 2025
- Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialThe Lancet Oncology, 2023
- Estimating design operating characteristics in Bayesian adaptive clinical trialsCanadian Journal of Statistics, 2022
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerNew England Journal of Medicine, 2019
- Using simulation studies to evaluate statistical methodsStatistics in Medicine, 2019
- Unified Methods for Censored Longitudinal Data and Causality2003
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987
- The statistical power of abnormal-social psychological research: A review.The Journal of Abnormal and Social Psychology, 1962